

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

ANAND et al.

Appln. No.: 09/781,311

Filed: February 13, 2001

FOR: METHODS

Group Art Unit: To Be Assigned

Examiner: To Be Assigned



Date: July 24, 2001

SUBMISSION UNDER 37 CFR § 1.821 ET SEQ.

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notice to File Corrected Application Papers mailed May 25, 2001, please enter the attached substitute paper and computer readable forms of the Sequence Listing in lieu of the original Sequence Listing submitted February 13, 2001. A copy of the Notice to File Corrected Application Papers is enclosed.

The paper and computer readable forms of the Sequence Listing do not add new matter, and are being submitted in accordance with 37 CFR § 1.821(e).

Furthermore, Statement pursuant to 37 CFR § 182(f) is submitted herewith.


In view of the above, it is respectfully submitted that this application complies with the Requirements for Patent Applications Containing Nucleotide Sequence and/ or Amino Acid Sequence Disclosures pursuant to 37 CFR §§ 1.821 et seq.

If any further information is needed, the Examiner is invited to contact the undersigned.

Respectfully Submitted,

PILLSBURY WINTHROP LLP

By:



Donald J. Bird
Registration No. 25,323
Tel. No.: (703) 905-2018
Fax No.: (703) 905-2500

Pillsbury Winthrop LLP
1600 Tysons Boulevard
McLean, VA 22120
DJB:amx

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Pat Seq/ 0360
PATENT APPLICATION

Inventor(s): ANAND et al.

Appl. No.: 09

Series Code ↑

Serial No. ↑

Filed: February 13, 2001

Hon. Commissioner of Patents

Washington, D.C. 20231

Group Art Unit To Be Assigned


Examiner: To Be Assigned

Atty. Dkt. P 0277090 PHM.70667/US

M#

Client Ref

Appl. Title: METHODS



Sir:

REPLY/AMENDMENT/LETTER

Date: July 24, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

A. ☒ NOT madeB. ☐ WithdrawnC. ☐ made herewithD. ☐ made previously

For B & C

See **Required****Separate Paper**

(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	33	**minus 33 0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	12	***minus 12 0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)		add	+ \$270/\$135 =	+ \$0	104/204
5. Original due Date: July 25, 2001	<input type="checkbox"/> NONE				
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (Usable only for ≤ 2mo.OA --- 4 mos) (Usable only for 30 day/1mo.OA --- 5 mos)	\$110/\$55 = \$390/\$195 = \$890/\$445 = \$1390/\$695= \$1890/\$945=	+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract		- \$0			
8.					
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$0		148/248
10. If IDS attached requires Official Fee under Rule 97 (c),	add	+ \$180	+ \$0		126
or if Rule 97(d) Request	add	+ \$180	+ \$0		126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$710/355	+ \$0		146/246
12. No. of additional inventions for examination per Rule 129(b)		x \$710/355 ea	+ \$0		149/249
13. Request for Continued Examination (RCE)		+ \$710/355	+ \$0		1179/1279
14. Petition fee for			+ \$0		
15.					
TOTAL FEE ENCLOSED =				\$0	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 009901 0277090

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Donald J. Bird

Sig:

Reg. No. 25323

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: DJB/AMX

Fax: (703) 905-2500

Tel: (703) 905-2018

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/781,311	02/13/2001	Rakesh Anand	P 277090 PH70667/US

RECEIVED

CONFIRMATION NO. 5187

FORMALITIES LETTER

Pillsbury Madison & Sutro LLP
Intellectual Property Group
East Tower, Ninth Floor
1100 New York Avenue, N.W.
Washington, DC 20005-3918

PILLSBURY WINTHROP LLP/DO



OC000000006118121

MAY 31 2001

CL# 9901 MT# 277090
ATTY(S) DJB MXR
DUE: 7-25-01
DKT BY (1) DJB (2) IEH

Date Mailed: 05/25/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)


The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY